Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 20, 2024

Primary Completion Date

January 20, 2026

Study Completion Date

March 20, 2026

Conditions
Leptomeningeal Metastasis
Interventions
DRUG

Pemetrexed

Pemetrexed 15 mg was administered with dexamethasone 5 mg via intraventricular or via lumbar puncture. First, induction intrathecal chemotherapy, twice per week for 2 weeks; then consolidation intrathecal chemotherapy, once per week for 4 weeks; and maintenance intrathecal chemotherapy, once per month until disease progression or unmanageable drug-related toxicity.

All Listed Sponsors
lead

Guangzhou Medical University

OTHER

NCT06296745 - Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib. | Biotech Hunter | Biotech Hunter